Akebia Therapeutics appoints Richard Malabre as Chief Accounting Officer

Akebia Therapeutics, Inc.

Richard C. Malabre named CAO effective January 8, 2024, reporting to CFO Ellen Snow.
Base salary of $380,000; annual cash bonus target up to 35% of base salary.
Granted options for 336,000 shares (4-year vest) and RSUs for 223,950 shares (3-year vest).
Malabre previously CFO of Ultivue, Inc. and VP/Corporate Controller at Oxford Immunotec.
Company will enter into standard Indemnification and Executive Severance Agreements.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Richard C. Malabre

Chief Accounting Officer

AKBA · Akebia Therapeutics, Inc.

Effective: 2024-01-08
Filed: January 8, 2024, 6:59 PM ET

On January 8, 2024, Akebia Therapeutics, Inc. (the “Company”) announced the appointment of Richard C. Malabre as Chief Accounting Officer and principal accounting officer, effective January 8, 2024 (the “Effective Date”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Richard C. Malabre was appointed as Chief Accounting Officer at Akebia Therapeutics, Inc..

Action: appointed
Role: Chief Accounting Officer

Exact text from the filing

On January 8, 2024, Akebia Therapeutics, Inc. (the “Company”) announced the appointment of Richard C. Malabre as Chief Accounting Officer and principal accounting officer, effective January 8, 2024 (the “Effective Date”).

View on SEC.gov

Akebia Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001517022-24-000007

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.